denosumab
amgen,daiichi sankyo
['denosumab']
 oral bisphos-unreliable absorption, 20% gi aes, monitor btms zoledronate-flu like illness-slow infusion rate, dose longer than every 12 months bisphos generally avoided in crcl &lt;30ml denosumab - more potent than bisphos, monitor ca in ckd #acrambassador 
mom,rheumatologist,VP @PaRheum, local leader @AWIRGROUP,#ACRambassador, #ACR22  Tweets#medical advice